Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Riendeau

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Bioorganic & Medicinal Chemistry Letters|November 27, 1999
A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitorsC S Li, W C Black, C Brideau, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitorsR W Friesen, C Brideau, C C Chan, et al.
Bioorganic & Medicinal Chemistry Letters|December 29, 2000
Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx)D A Nicoll-Griffith, J A Yergey, L A Trimble, et al.
Journal of Medicinal Chemistry|August 29, 1997
Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010P Hamel, D Riendeau, C Brideau, et al.
Journal of Medicinal Chemistry|September 27, 1996
Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stabilityD Delorme, Y Ducharme, C Brideau, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitorP Prasit, Z Wang, C Brideau, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2D Riendeau, M D Percival, C Brideau, et al.
British Journal of Pharmacology|May 1, 1997
Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitorD Riendeau, M D Percival, S Boyce, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Bioorganic & Medicinal Chemistry Letters|November 27, 1999
A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitorsC S Li, W C Black, C Brideau, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitorsR W Friesen, C Brideau, C C Chan, et al.
Bioorganic & Medicinal Chemistry Letters|December 29, 2000
Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx)D A Nicoll-Griffith, J A Yergey, L A Trimble, et al.
Journal of Medicinal Chemistry|August 29, 1997
Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010P Hamel, D Riendeau, C Brideau, et al.
Journal of Medicinal Chemistry|September 27, 1996
Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stabilityD Delorme, Y Ducharme, C Brideau, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitorP Prasit, Z Wang, C Brideau, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2D Riendeau, M D Percival, C Brideau, et al.
British Journal of Pharmacology|May 1, 1997
Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitorD Riendeau, M D Percival, S Boyce, et al.
Pageof 8